Cargando…
Severe COVID-19: Drugs and Clinical Trials
By January of 2023, the COVID-19 pandemic had led to a reported total of 6,700,883 deaths and 662,631,114 cases worldwide. To date, there have been no effective therapies or standardized treatment schemes for this disease; therefore, the search for effective prophylactic and therapeutic strategies i...
Autores principales: | Ceja-Gálvez, Hazael Ramiro, Renteria-Flores, Francisco Israel, Nicoletti, Ferdinando, Hernández-Bello, Jorge, Macedo-Ojeda, Gabriela, Muñoz-Valle, José Francisco |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10142549/ https://www.ncbi.nlm.nih.gov/pubmed/37109231 http://dx.doi.org/10.3390/jcm12082893 |
Ejemplares similares
-
Prevalence of symptoms, comorbidities, and reinfections in individuals infected with Wild-Type SARS-CoV-2, Delta, or Omicron variants: a comparative study in western Mexico
por: Peña Rodríguez, Marcela, et al.
Publicado: (2023) -
Potential immunomodulatory effects of vitamin D in the prevention of severe coronavirus disease 2019: An ally for Latin America (Review)
por: Turrubiates-Hernández, Francisco Javier, et al.
Publicado: (2021) -
The PI3K/Akt/mTOR pathway: A potential pharmacological target in COVID-19
por: Basile, Maria Sofia, et al.
Publicado: (2022) -
Transcriptional upregulation of galectin-3 in multiple sclerosis
por: Mangano, Katia, et al.
Publicado: (2023) -
A review: Antibody-dependent enhancement in COVID-19: The not so
friendly side of antibodies
por: Sánchez-Zuno, Gabriela Athziri, et al.
Publicado: (2021)